ATAI Life Sciences N.V. (NASDAQ: ATAI) Stock Information | RedChip

ATAI Life Sciences N.V. (NASDAQ: ATAI) Listen to this Section


$1.25
+0.0750 ( +6.41% ) 1.2M

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

Market Data


Open


$1.25

Previous close


$1.17

Volume


1.2M

Market cap


$209.75M

Day range


$1.18 - $1.25

52 week range


$1.03 - $2.85

Insider Ownership Transactions

Total Amount Purchased: -1,226,253.00 | $ -1,526,684.99

Date Type Amount Purchased Purchaser
2024-06-14 Sale -103000.00 Angermayer Christian
2024-06-14 Sale -206000.00 Fischer Laurent
2024-06-14 Sale -103000.00 Smiley Andrea Heslin
2024-06-14 Sale -103000.00 Kalali Amir H
2024-06-14 Sale -103000.00 Auerbach Michael
2024-06-14 Sale -206000.00 Braunstein Scott
2024-06-14 Sale -103000.00 JOHNSON SABRINA MARTUCCI
2024-05-20 Sale -151303.00 Brand Florian
2024-05-03 Sale 0.00 ATAI Life Sciences N.V.
2024-04-17 Sale -147950.00 Apeiron Investment Group Ltd.

SEC Fillings


Form Type Description Pages Date
8-k 8K-related 14 Aug 14, 2024
10-q Quarterly Reports 101 Aug 13, 2024
8-k 8K-related 15 Aug 13, 2024
4 Insider transactions 1 Jun 14, 2024
4 Insider transactions 1 Jun 14, 2024
4 Insider transactions 1 Jun 14, 2024
4 Insider transactions 1 Jun 14, 2024
4 Insider transactions 1 Jun 14, 2024
4 Insider transactions 1 Jun 14, 2024
4 Insider transactions 1 Jun 14, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.